Cognitive impairment following breast cancer treatments: an umbrella review

• Published in: The oncologist (Dayton, Ohio) Ohio), 2024-07, Vol.29 (7), p.e848-e863
• Main Authors: Oliva, Giulia, Giustiniani, Andreina, Danesin, Laura, Burgio, Francesca, Arcara, Giorgio, Conte, Pierfranco
• Format: Article
• Language: English
• Subjects: Breast Cancer; Breast Neoplasms - complications; Breast Neoplasms - drug therapy; Breast Neoplasms - psychology; Breast Neoplasms - therapy; Cancer; Care and treatment; Cognition disorders; Cognitive Dysfunction - etiology; Female; Humans; Oncology, Experimental; Physiological aspects; Risk factors
• ISSN: 1083-7159; 1549-490X; 1549-490X
• DOI: 10.1093/oncolo/oyae090

Cancer-related cognitive impairment (CRCI) refers to a cognitive decline associated with cancer or its treatments. While research into CRCI is expanding, evidence remains scattered due to differences in study designs, methodologies, and definitions. The present umbrella review aims to provide a comprehensive overview of the current evidence regarding the impact of different breast cancer therapies on cognitive functioning, with a particular focus on the interplay among objective cognitive deficits (ie, measured with standardized tests), subjective cognitive concerns, (ie, self-reported), and other mediating psycho-physical factors. The search was made in Pubmed, Embase, and Scopus for articles published until July 2023, following the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analysis protocol. Chemotherapy and endocrine therapy appear consistently associated with CRCI in patients with breast cancer, primarily affecting memory, attention/concentration, executive functioning, and processing speed. Subjective cognitive concerns were often found weakly or not associated with neuropsychological test results, while overall CRCI seemed consistently associated with psychological distress, fatigue, sleep quality, and inflammatory and biological factors. Current evidence suggests that CRCI is common after chemotherapy and endocrine therapy for breast cancer. However, heterogeneity in study designs and the scarcity of studies on more recent treatments such as targeted therapies and immunotherapies, highlight the need for more systematic and harmonized studies, possibly taking into account the complex and multifactorial etiology of CRCI. This may provide valuable insights into CRCI's underlying mechanisms and potential new ways to treat it.